Drugs / 4D-710
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05248230 | Mar 2022 → Jun 2027 expected | cystic fibrosis | 4D Molecular Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2025-12-17 | 4D Molecular Therapeutics | Results 4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease 4dmoleculartherapeutics.com ↗
4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced positive interim clinical data from the 4D-710 Phase 1 AEROW clinical trial for the treatment of cystic fibrosis (CF) lung disease. |
| 2024-06-06 | 4D Molecular Therapeutics | Results 4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference 4dmoleculartherapeutics.com ↗
4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced positive interim clinical data from the 4D-710 Phase 1/2 AEROW clinical trial for the treatment of cystic fibrosis (CF) lung disease. |
| 2024-01-23 | 4D Molecular Therapeutics | Regulatory 4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease 4dmoleculartherapeutics.com ↗ |
| 2023-11-09 | 4D Molecular Therapeutics | Results 4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights 4dmoleculartherapeutics.com ↗
Announced positive interim data from 4D-710 Phase 1/2 AEROW clinical trial for cystic fibrosis; update on FDA interaction expected in Q1 2024 |
| 2023-11-01 | 4D Molecular Therapeutics | Results 4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFC 4dmoleculartherapeutics.com ↗
Aerosolized 4D-710 was generally well tolerated with no inflammation in any lung biopsy across Cohorts 1 and 2 (1E15 & 2E15 vg; n=7) with up to 17 months follow-up |
| 2023-06-07 | 4D Molecular Therapeutics | Results 4DMT Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at the ECFS 46th Annual Meeting 4dmoleculartherapeutics.com ↗ |
| 2022-11-03 | 4D Molecular Therapeutics | Results 4D Molecular Therapeutics Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease at NACFC 2022 4dmoleculartherapeutics.com ↗
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that interim clinical data from the Phase 1/2 clinical trial of 4D-710 for cystic fibrosis lung disease were presented at the North American Cystic Fibrosis Conference (NACFC). |
| 2022-11-03 | 4D Molecular Therapeutics | Results 4D Molecular Therapeutics Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease at NACFC 2022 4dmoleculartherapeutics.com ↗
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that interim clinical data from the Phase 1/2 clinical trial of 4D-710 for cystic fibrosis lung disease were presented at the North American Cystic Fibrosis Conference (NACFC). |
| 2021-10-06 | 4D Molecular Therapeutics | Regulatory 4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-710, an A101 Vector-based, Aerosol-delivered Gene Therapy for the Treatment of Cystic Fibrosis Lung Disease 4dmoleculartherapeutics.com ↗
4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for 4D-710 for the treatment of patients with cystic fibrosis. |
All press releases naming this drug 18 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4D-710 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05248230 ↗ |
| Action | Restore | “Delivery of a functional CFTR transgene to airway epithelial cells (AEC) offers the potential to provide durable restoration of normal CFTR function.” PMID 41124321 ↗ Jul 2026 |
| Modality | Gene therapy (AAV / viral vector) | “4D-710 is an adeno-associated virus (AAV) gene therapy” NCT05248230 ↗ |
| Route | Inhaled | “single inhalational administration of 4D-710” NCT05248230 ↗ |
| Target | CFTR | “a gene therapy comprising the A101 vector and a CFTR transgene with a partial deletion in the regulatory domain (CFTRΔR) to facilitate vector packaging” PMID 41124321 ↗ Jul 2026 |